Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Smit, Egbert F
906  Ergebnisse:
Personensuche X
?
1

Identification of protein biomarkers for prediction of resp..:

Böttger, Franziska ; Radonic, Teodora ; Bahce, Idris...
Molecular Oncology.  18 (2024)  6 - p. 1417-1436 , 2024
Link: https://doi.org/10.1002/..
 
?
2

The role of anti-EGFR therapies in EGFR-TKI-resistant advan..:

Ciardiello, Fortunato ; Hirsch, Fred R. ; Pirker, Robert...
Cancer Treatment Reviews.  122 (2024)  - p. 102664 , 2024
Link: https://doi.org/10.1016/..
 
?
3

Treatment decision for recurrences in non-small cell lung c..:

Mirza, Myriam ; Shrivastava, Aseem ; Matthews, Cecile...
Frontiers in Oncology.  13 (2024)  - p. , 2024
Link: https://doi.org/10.3389/..
 
?
4

Recommendations for reporting tissue and circulating tumour..:

Malapelle, Umberto ; Leighl, Natasha ; Addeo, Alfredo...
British Journal of Cancer.  , 2024
Link: https://doi.org/10.1038/..
 
?
5

A plain language summary of the PHAROS study: the combinati..:

Riely, Gregory J ; Smit, Egbert F ; Ahn, Myung-Ju...
Future Oncology.  20 (2024)  16 - p. 1047-1055 , 2024
Link: https://doi.org/10.2217/..
 
?
6

Blood platelet RNA profiles do not enable for nivolumab res..:

Muller, Mirte ; Best, Myron G. ; van der Noort, Vincent...
Tumor Biology.  46 (2024)  s1 - p. S327-S340 , 2024
Link: https://doi.org/10.3233/..
 
?
7

Cemiplimab in locally advanced or metastatic cutaneous squa..:

Verkerk, Karlijn ; Geurts, Birgit S. ; Zeverijn, Laurien J....
The Lancet Regional Health - Europe.  39 (2024)  - p. 100875 , 2024
Link: https://doi.org/10.1016/..
 
?
8

Model-Informed Development of a Cost-Saving Dosing Regimen ..:

Moes, Dirk J. A. R. ; Hendrikx, Jeroen J. M. A. ; Guchelaar, Henk-Jan...
Targeted Oncology.  , 2024
Link: https://doi.org/10.1007/..
 
?
9

Can blood-based markers predict RECIST progression in non-s..:

Yeghaian, Melda ; Tareco Bucho, Teresa M. ; de Bruin, Melissa...
Journal of Cancer Research and Clinical Oncology.  150 (2024)  6 - p. , 2024
Link: https://doi.org/10.1007/..
 
?
10

Integrated non-invasive diagnostics for prediction of survi..:

Yeghaian, Melda ; Bodalal, Zuhir ; Tareco Bucho, Teresa M....
Immuno-Oncology and Technology.  , 2024
Link: https://doi.org/10.1016/..
 
?
11

Combining Genomic Biomarkers to Guide Immunotherapy in Non–..:

van de Haar, Joris ; Mankor, Joanne M. ; Hummelink, Karlijn...
Clinical Cancer Research.  30 (2024)  7 - p. 1307-1318 , 2024
Link: https://doi.org/10.1158/..
 
?
12

Osimertinib Plasma Trough Concentration in Relation to Brai..:

Gulikers, Judith L. ; Veerman, G.D. Marijn ; Jebbink, Merel...
JTO Clinical and Research Reports.  5 (2024)  4 - p. 100656 , 2024
Link: https://doi.org/10.1016/..
 
?
13

BRAFV600E-mutant metastatic NSCLC: disease overview and tre..:

Planchard, David ; Sanborn, Rachel E. ; Negrao, Marcelo V...
npj Precision Oncology.  8 (2024)  1 - p. , 2024
Link: https://doi.org/10.1038/..
 
?
14

Trastuzumab deruxtecan in patients with metastatic non-smal..:

Smit, Egbert F ; Felip, Enriqueta ; Uprety, Dipesh...
The Lancet Oncology.  25 (2024)  4 - p. 439-454 , 2024
Link: https://doi.org/10.1016/..
 
?
15

Poziotinib for HER2 Exon 20-Mutated NSCLC: Addition or Burd..:

Borm, Frank.J. ; Smit, Egbert F.
Journal of Thoracic Oncology.  18 (2023)  8 - p. 964-966 , 2023
Link: https://doi.org/10.1016/..
 
1-15